title: [Effectiveness of maintenance azathioprine therapy without oral cyclosporine after severe attacks of ulcerative colitis refractory to endovenous steroids].
abstract: BACKGROUND
  Intravenous (i.v.) cyclosporine (CsA) has proved effective in controlling acute attacks of ulcerative colitis unresponsive to IV steroids. After the initial response to i.v. CsA, two alternatives for maintaining remission have been proposed: either double or triple association with immunosuppressors. The aim of this study was to evaluate the effectiveness of i.v. CsA, its adverse effects, and the subsequent long-term effectiveness of azathioprine/6-mercaptopurine without oral CsA.
  
  
  METHODS
  Intravenous CsA was administered for 10 days, at a dose of 4 mg/kg per day, to 20 patients diagnosed with a severe attack of ulcerative colitis who did not respond to IV steroid treatment. Patients who responded to CsA and could be discharged were administered azathioprine or 6-mercaptopurine associated with a decreasing dose of oral steroids, without oral CsA.
  
  
  RESULTS
  Sixty per cent (12/20) of the patients showed clinical-biological improvement after CsA administration, thus avoiding colectomy, and were discharged from hospital. Nine of the 12 responders (three withdrew from the study) were followed-up long term. Of these nine patients, four (44.4%) underwent colectomy, all before the sixth month of discharge. All adverse effects were mild, except for one death.
  
  
  CONCLUSIONS
  Intravenous CsA is effective in inducing remission of ulcerative colitis in severe attacks resistant to i.v. steroids. When treatment with azathioprine is administered without oral CsA, patients requiring colectomy need this procedure within the first 6 months of discharge.
authors.affiliation: Sección de Gastroenterología, Servicio de Patología Digestiva, Consorci Hospital General Universitari de Valencia, Valencia, España. josemahuguet@hotmail.com
authors.forename: José María
authors.initials: JM
authors.lastname: Huguet Malavés
authors.forename: Lucía
authors.initials: L
authors.lastname: Ruiz Sánchez
authors.forename: Ana Belén
authors.initials: AB
authors.lastname: Durá Ayet
authors.forename: Isabel
authors.initials: I
authors.lastname: Rodríguez García
authors.forename: Mercedes
authors.initials: M
authors.lastname: Latorre Sánchez
authors.forename: Luis
authors.initials: L
authors.lastname: Ferrer Arranz
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Tuset Ruiz
authors.forename: Alica
authors.initials: A
authors.lastname: Tomé Toyosato
authors.forename: Enrique
authors.initials: E
authors.lastname: Medina Chuliá
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D017211:Treatment Failure
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D006854:Hydrocortisone